Raymond James Financial Inc. acquired a new stake in shares of Bruker Co. (NASDAQ:BRKR - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 11,268 shares of the medical research company's stock, valued at approximately $661,000.
Other hedge funds have also added to or reduced their stakes in the company. Eagle Bay Advisors LLC raised its position in shares of Bruker by 2,324.1% in the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company's stock worth $41,000 after purchasing an additional 674 shares during the last quarter. UMB Bank n.a. raised its holdings in Bruker by 37.5% in the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock worth $53,000 after buying an additional 248 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Bruker by 47.5% in the fourth quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company's stock worth $75,000 after buying an additional 412 shares in the last quarter. Blue Trust Inc. lifted its stake in shares of Bruker by 13.5% in the fourth quarter. Blue Trust Inc. now owns 2,164 shares of the medical research company's stock worth $127,000 after buying an additional 257 shares in the last quarter. Finally, CIBC Asset Management Inc grew its holdings in shares of Bruker by 5.6% during the fourth quarter. CIBC Asset Management Inc now owns 4,233 shares of the medical research company's stock valued at $248,000 after buying an additional 223 shares during the last quarter. 79.52% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several research firms recently issued reports on BRKR. Citigroup lowered their price objective on Bruker from $75.00 to $50.00 and set a "buy" rating on the stock in a research report on Monday. Guggenheim reiterated a "buy" rating on shares of Bruker in a report on Monday, February 24th. Stifel Nicolaus decreased their target price on shares of Bruker from $70.00 to $57.00 and set a "hold" rating for the company in a research note on Friday, February 14th. Barclays reduced their price target on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating for the company in a research report on Thursday. Finally, Bank of America raised their target price on Bruker from $78.00 to $80.00 and gave the stock a "buy" rating in a report on Friday, December 13th. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $66.50.
Get Our Latest Report on BRKR
Bruker Price Performance
Shares of BRKR stock traded up $0.69 on Friday, reaching $38.76. The company's stock had a trading volume of 3,139,890 shares, compared to its average volume of 1,467,986. The company has a market capitalization of $5.88 billion, a price-to-earnings ratio of 51.00, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. The stock's fifty day simple moving average is $46.16 and its 200-day simple moving average is $54.75. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15. Bruker Co. has a 1 year low of $34.10 and a 1 year high of $90.03.
Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping analysts' consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. Analysts forecast that Bruker Co. will post 2.69 earnings per share for the current fiscal year.
Bruker Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Monday, March 17th were paid a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.52%. The ex-dividend date of this dividend was Monday, March 17th. Bruker's payout ratio is 26.32%.
About Bruker
(
Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Recommended Stories
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
